Vyne Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $121 | $198 | $98 | $76 |
Gross Profit | 121 | 198 | 98 | 76 |
EBITDA | -13,091 | -9,395 | -7,380 | -6,832 |
EBIT | -10,396 | -6,603 | -6,577 | |
Net Income | -12,157 | -9,395 | -6,241 | -6,188 |
Net Change In Cash | 121 | 198 | 98 | 76 |
Free Cash Flow | -8,510 | -8,481 | -7,982 | -5,137 |
Cash | 16,272 | 29,655 | 19,119 | 30,674 |
Basic Shares | 42,587 | 42,586 | 42,581 | 3,105 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $424 | $477 | $14,755 | $20,993 |
Gross Profit | 424 | 477 | 11,407 | 19,601 |
EBITDA | -29,258 | -34,223 | -38,937 | -251,095 |
EBIT | -29,003 | -34,295 | -39,046 | -251,436 |
Net Income | -28,452 | -33,945 | -73,329 | -255,568 |
Net Change In Cash | 424 | 477 | 14,755 | 20,993 |
Free Cash Flow | -25,341 | -29,200 | -56,367 | -137,195 |
Cash | 30,620 | 30,908 | 42,250 | 57,563 |
Basic Shares | 10,273 | 3,185 | 2,858 | 1,800 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.29 |
2024-06-30 | -$0.22 |
2024-03-31 | -$0.15 |
2023-12-31 | -$0.20 |
